Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EstroGel dose-finding for menopausal symptoms
NCT00160173Phase 4Completed
- Sponsor
- ASCEND Therapeutics US, LLC
- Start
- Dec 2004
- Primary completion
- Sep 2005
- Modality
- Hormone, Biologic
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of estradiol in vasomotor symptoms of menopause (VMS) and vulvovaginal atrophy (VVA) (3 arms), sponsored by ASCEND Therapeutics US, LLC. Primary endpoint: Vasomotor symptoms associated with menopause at 12 weeks. Started Dec 2004; status: completed.
02
Drugs
estradiol
03
Conditions
vasomotor symptoms of menopause (VMS)vulvovaginal atrophy (VVA)
Beyond the preview
Go deeper on NCT00160173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00160173.